BRCA1 and cancer: It is thought that heterozygosity status-reduced wild-type BRCA1 protein dosage (haploinsufficiency) and/or the presence of a mutant BRCA1 protein may affect BRCA1 functions and heighten the risk of cancer promoting mutations.